2022: Fitzpatrick Effectively Voted Against Reaffirming The Preemption
Of The FDA's Authority Regarding Reproductive Health Product Approvals
Over State Or Local Regulations That Restrict Reproductive Health
Products. In December 2022, according to the Congressional Quarterly,
Fitzpatrick voted against the "automatic agreement to [...] a
resolution (H Res 1434) that would reaffirm that the Food and Drug
Administration's authorities to approve or authorize reproductive health
products have a preemptive effect with respect to any state or local
laws that inhibit access to or use of any reproductive health product."
The vote was on the adoption of the rule and automatic agreement to the
resolution. The House adopted the rule and adopted the resolution by a
vote of 216 -- 193. [House Vote 531,
12/21/22; Congressional
Quarterly, 12/21/22;
Congressional Actions, H.Res.
1529;
Congressional Actions, H.Res.
1434]